Hyperhidrosis Treatments
Defines medical necessity criteria for iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy (ETS) for primary hyperhidrosis for Health Net/Centene-affiliated health plans and affected members/enrollees and providers.
Updated criteria I.E.3. by removing (hyperhidrosis often improves pregnancy) and added epilepsy to contraindications.
Updated Criteria II.B. to greater than 55 beats per minute (resting heart rate).
Added counseling requirement on risks of procedure for ETS candidacy (Criteria III.I).
Removed six-month time frame requirement for trial of conservative management and removed certain prior pharmacotherapy trial language.
Coverage Criteria
I. Iontophoresis (medically necessary)
Covered when ALL of the following are met:
From Policy/Criteria I.A through I.D
II. Surgical excision of axillary sweat glands (medically necessary)
Covered when ALL of the following are met:
From Policy/Criteria II.A through II.C
III. Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis (medically necessary)
Covered when ALL of the following are met:
From Policy/Criteria III.A through III.I and revision notes adding counseling requirement and heart rate/BMI thresholds
IV. Other treatments
Policy IV
The policy does not support microwave therapy or liposuction when used as the sole method to remove axillary sweat glands. The document states there is insufficient published peer‑reviewed evidence to support these and similar treatments for hyperhidrosis, and specifically calls out microwave therapy and liposuction as examples of unsupported approaches. The miraDry System is FDA‑cleared for primary axillary hyperhidrosis but national guidance (NICE) characterizes current evidence for transcutaneous microwave ablation as inadequate in quantity and quality and recommends its use only with special governance, consent, audit, or research arrangements.
All treatments for hyperhidrosis that lack sufficient peer‑reviewed evidence are considered unsupported by this policy. Examples explicitly included are diathermy/microwave modalities and liposuction performed alone for axillary sweat gland removal. The policy emphasizes the insufficiency of published evidence for these approaches and references regulatory and health‑technology guidance noting limited or inadequate data to establish safety and efficacy.
Coding
| 11450 | Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair |
| 11451 | Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair |
| 15877 | Suction assisted lipectomy; trunk |
| 15878 | Suction assisted lipectomy; upper extremity |
| 32664 | Thoracoscopy, surgical; with thoracic sympathectomy |
| 97024 | Application of a modality to 1 or more areas; diathermy (eg, microwave) |
| 97033 | Application of a modality to 1 or more areas; iontophoresis, each 15 minutes |
Provider Actions & Authorization
Prior Authorization Required
Prior authorization is required per plan for procedures referenced by CPT codes when applicable. Providers should obtain authorization before scheduling or performing procedures such as iontophoresis (CPT 97033), thoracoscopic sympathectomy (CPT 32664), excision of axillary sweat glands or related excision codes (e.g., 11450, 11451), and other listed procedures. Inclusion of CPT codes here is informational; verify plan-specific authorization rules and use the most current coding guidance when submitting claims.
Prior Therapies Required Before Surgical Excision or ETS
Before surgical axillary excision or endoscopic thoracic sympathectomy (ETS) is approved, documentation must show the member failed at least one prior non‑surgical therapy: either a trial of iontophoresis (per I. criteria) or a trial of botulinum toxin (per policy criteria). Requests lacking evidence of these prior therapies are subject to denial.
- One of the following must be documented prior to approval for axillary excision or ETS: iontophoresis OR trial of botulinum toxin.
- If prior therapies were contraindicated or not feasible, clinical rationale and supporting documentation must be provided.
Requests Not Meeting Criteria Are Subject to Denial
Requests for iontophoresis, axillary excision, or ETS that do not meet the medical necessity criteria are subject to denial. Denial risk is increased when required documentation is missing, prior therapies have not been attempted when indicated, or contraindications are present.
- Denial risks include: missing documentation of primary hyperhidrosis diagnosis, absence of medical complications or significant functional disruption, no record of prior conservative therapy (e.g., aluminum chloride) for iontophoresis requests, or no trial of iontophoresis/botulinum toxin for surgical requests.
- Verify contraindications (e.g., pacemaker, arrhythmia, pregnancy, epilepsy, certain metal implants) prior to submitting request.
Required Documentation Elements
Documentation submitted with prior authorization requests should clearly demonstrate: diagnosis of primary hyperhidrosis; presence of medical complications (for example, skin maceration with secondary infection) or significant constant disruption of professional/social life due to sweating; details of conservative management tried (including adherence to aluminum chloride hexahydrate/Drysol or reason for intolerance); results of iontophoresis or botulinum toxin trials when applicable; and absence of contraindications. Include clinical notes, treatment dates, response to therapies, and counseling about surgical risks when surgery is requested.
- Document primary hyperhidrosis diagnosis and symptom onset.
- Document medical complications or significant functional impairment attributable to sweating.
- Provide evidence of conservative management and trial dates (topical aluminum chloride, iontophoresis, botulinum toxin) and outcomes.
- State any contraindications (pacemaker, arrhythmias, pregnancy, metal implants, epilepsy) or rationale if treatments were not tried.
- For ETS requests, include counseling that the member was informed of procedure risks.
Definitions
Background
Primary focal hyperhidrosis is an idiopathic condition characterized by visible, excessive sweating beyond physiological needs and is commonly localized to the axillae, palms, or soles. It is defined in the literature as persistent for at least six months without an apparent secondary cause and is thought to result from sympathetic hyperactivity. The condition frequently produces substantial emotional, social, or occupational impairment and is distinct from secondary hyperhidrosis, which is typically generalized or craniofacial and related to medications or underlying medical disorders.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.